Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Anti-Cancer Drugs

Volumn 7, Issue 5, 1996, Pages 548-557

  Shirasaka, Tetsuhiko ^a   Shimamato, Yuji ^a   Ohshimo, Hideyuki ^a   Yamaguchi, Masahiro ^a   Kato, Toshiyuki ^a   Yonekura, Kazuhiko ^a   Fukushima, Masakazu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; cytotoxicity; gastrointestinal toxicity; novel; oral; S 1; tegafur

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; FLUOROURACIL; NEW DRUG; OXONIC ACID; TEGAFUR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; YOSHIDA SARCOMA;

EID: 0029835349     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199607000-00010     Document Type: Article

References (40)

1. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-atlantic oncology program study. J Clin Oncol 1989; 7: 425-32.
2. Quebbeman E, Ausman R, Hansen R, et al. Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. J Surg Oncol 1985; 30: 60-5.
3. Hansen R, Quebbeman E, Ausman R, et al. Continuous systemic 5-fluorouracil (5-FU) infusion in advanced colorectal cancer. Results in 91 patients. J Surg Oncol 1989; 40: 177-8.
4. Barbounis VP, Kalofonos HP, Munro AJ, et al. Treatment of colorectal cancer and other malignancies with continuous infusion of 5-fluorouracil. Anticancer Res 1989; 9: 33-40.
5. Yamao T, Shimada Y, Kondo H, et al. Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. Jpn J Clin Oncol 1995; 25: 46-50.
6. Moynihan T, Hansen R, Anderson T, et al. Continuous 5-fluorouracil (5-FU) infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11: 461-4.
7. Huan S, Pazdur RT, Singhakowinta A, et al. Low dose continuous infusion 5-fluoroacil. Evaluation in advanced breast carcinoma. Cancer 1989; 63: 419-22.
8. Hansen R, Quebbeman E, Ritch P, et al. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas. Am J Med Sci 1988; 295: 91-3.
9. Hansen R, Moynihan T, Beatty P, et al. Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology 1991; 37: 358-61.
10. Caballero GA, Ausman RK, Quebbeman EJ, et al. Long-term, ambulatory, continuous intravenous infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 1985; 69: 13-5.
11. Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Res 1979; 39: 2406-13.
12. Shrasaka T, Shimamoto Y, Fukushima M. Inhibition of oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-9.
13. Hillcoat BL, McCulloch PB, Figueredo AT, et al. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated drug infusion. Br J Cancer 1978; 38: 719-24.
14. Gudauskas G, Goldie JH. The pharmacokinetics of high-dose continuous 5-flourouracil infusions. Proc Am Ass Cancer Res 1978; 19: 230.
15. Fox RM, Woods RL, Tattersall MHN, et al. Allopurinol modulation of fluorouracil toxicity. Cancer Chemother Pharmacol 1981; 5: 151-5.
16. Howell SB, Wung WE, Taetle R, et al. Modulation of 5-fluourouracil toxicity by allopurinol in man. Cancer 1981; 48: 1281-9.
17. Sampson DC, Fox RM, Tattersall MHN, et al. A rapid high-performance liquid chromatographic method for quantitation of 5-fluorouracil in plasma after continuing intravenous infusion. Ann Clin Biochem 1982; 19: 125-8.
18. Hornbeck CL, Floyd RA, Byfield JE, et al. Cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxipurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation. Cancer Treat Rep 1982; 66: 571-3.
19. Boublil JL, Milano G, Khater R, et al. Continuous 5-day regional chemotherapy by 5-fluourouracil in colon carcinoma: pharmacokinetic evaluation. Br J Cancer 1985; 52: 15-20.
20. Erlichman C, Fine S, Elhakim T. Plasma pharmacokinetics of 5-FU given continuous infusion with allopurinal. Cancer Treat Rep 1986; 70: 903-4.
21. Petit E, Milano G, Levi F. Circadian rhythm-varing plasma concentration of 5-fluorouracil during five day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676-9.
22. Harris BE, Song R, Soong S, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluourouracil levels with evidence for circadian variation of enzyme activity and plasma levels in patients receiving 5-fluourouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201.
23. Metzger G, Massari C, Etienne M-C, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther 1994; 56: 190-201.
24. Harris BE, Song R, He Y-J, et al. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol 1988; 37: 4759-62.
25. Fujii S, Shimamoto Y, Shirasaka T, et al. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats. Jpn J Cancer Res 1989; 80: 167-72.
26. Heggie GD, Sommadossi J-P, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and it metabolites in plasma, urine and bile. Cancer Res 1987; 47: 2203-06.
27. Tatsumi K, Fukushima M, Shirasaka T, et al. Inhibitory effects of pyrimidine, Barbituric acid and pyridine derivatives on 5-fluourouracil degradation in rat liver extracts. Gann 1987; 78: 748-55.
28. Hiller SA, Zhuk PA, Lidak MJ. Analogs of pyrimidine nucleosides, I. N-(a-furanidyl) derivatives of natural pyrimidine based and their antimetabolites. Dokl Akad Kauk SSSR 1967; 176: 332-5.
29. Fujii S, Ikenaka K, Fukishima M, et al. Effect of uracil and it derivatives on antitumor activity of 5-fluourouracil and 1-(2-tetrahydrofuryl)-5-flourouracil. Gann 1978; 69: 763-72.
30. Ikenaka K, Shirasaka T, Kitano S, et al. Effect of uracil on metabolism of 5-fluorouracil in vitro. Jpn J Cancer Res 1979; 70: 353-9.
31. Fleming RA, Milano GA, Gaspard MH, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J cancer 1993; 29A: 740-44.
32. Peters GJ, van der Wilt CL, van Groeningen CJ. Predictive value of thymidylate synthetase and dihydropyrimidine dehydrogenase. Eur J Cancer 1994; 30A: 1408-11.
33. Beck A, Etienne MC, Che'radame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to flurouracil. Eur J Cancer 1994; 30A: 1517-22.
34. Keizer HJ, De Bruijn EA, Tjaden UR, et al. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine. J Cancer Res Clin Oncol 1994; 120: 545-9.
35. Burris H, Schilsky R, Fields S, et al. Initial phase I trial of the dihydropyrimidine dehydrogenase inactivator 5-ethynyluracil (776C85) plus 5-fluorouracil. Am Soc Clin Oncol Proc 1995; 14: 171 (abstr 368).
36. Adjei AA, Doucette M, Spector T, et al. 5-Ethynyluracil (776C85), an inhibitor of dihydropyrimidine dehydrogenase (DPD), permits reliable oral dosing of 5-fluorouracil (5-FU) and prolongs its half-life (1/2 T). Am Soc Clin Oncol Proc 1995; 14: 459 (abstr 1478).
37. Porter DJT, Chestnut WG, Merrill BM, et al. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethyluracil. J Biol Chem 1992; 267: 5236-42.
38. Schwartz PM, Dunigan JM, Marsh JC, et al. Allopurinol modulation of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res 1980; 40: 1885-9.
39. Kroener JF, Saleh F, Howell SB. 5-FU and allopurinol: toxicity modulation and phase II results in colon cancer. Cancer Treat Rep 1982, 66: 1133-7.
40. Wooley PV, Ayoob MT, Smith FP, et al. A controlled trial of the effect of 4-hydroxypyrazolo-pyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil. J Clin Oncol 1985; 3: 103-9.